Skip to main content
SpringerLink
Log in

Wertigkeit der Chemotherapie in der Behandlung des fortgeschrittenen Prostatakarzinoms

  • Conference paper
Behandlung des fortgeschrittenen Prostatakarzinoms

Zusammenfassung

Das Prostatakarzinom ist in der Bundesrepublik Deutschland und in den Vereinigten Staaten der zweithäufigste maligne Tumor bei Männern [1, 5, 43]. Bei der Diagnosestellung eines Prostatakarzinoms liegt bereits bei der Mehrzahl der Patienten ein fortgeschrittenes Tumorstadium C oder D vor [7, 35]. 20–30% der Tumoren sind primär hormonresistent und 50% der Patienten mit Metastasen haben innerhalb von 1,5–3 Jahren nach Beginn der hormonellen Therapie einen Tumorprogreß [7, 42]. Die mediane Überlebenszeit dieser Patienten beträgt dann weniger als 40 Wochen [13]. Diese Daten weisen daraufhin, daß zusätzliche Formen der Therapie zur Behandlung des inoperablen Prostatakarzinoms erforderlich sind. Eine Möglichkeit stellt hier die Chemotherapie dar. In der Vergangenheit wurden umfangreiche Studien zur Überprüfung der Wirksamkeit chemotherapeutischer Substanzen bei diesem Tumor durchgeführt. Die Ergebnisse sind jedoch insgesamt enttäuschend.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altwein JE, Jacobi GH (1980) Hormontherapie des Prostatakarzinoms. Urologe A 19: 350–357

    PubMed  CAS  Google Scholar 

  2. Ansfield FJ, Schroeder J, Curreri AR (1962) Five years’ clinical experience with 5fluorouracil. JAMA 181: 295–299

    PubMed  CAS  Google Scholar 

  3. Blum RH (1975) An overview of studies with Adriamycin (NSC-123127) in the United States. Cancer Chemother Rep 6 (Part 3): 247–251

    Google Scholar 

  4. Burk K, Schultze-Seemann W, de Riese W, Hanke P, Weber W (1986) Die ambulante cytostatische Therapie des hormonrefraktären Prostatakarzinoms mit 4-Epirubicin. Deutscher Kongreß für Urologie, abstract 150

    Google Scholar 

  5. Carter SK, Wasserman TH (1975) The chemotherapy of urologie cancer. Cancer 36: 729–747

    Article  PubMed  CAS  Google Scholar 

  6. Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostate cancer. Cancer 42: 2546–2552

    Article  PubMed  CAS  Google Scholar 

  7. Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419–424

    Article  PubMed  CAS  Google Scholar 

  8. Cutler SJ, Young JL (1975) Third national cancer survey: incidence data. Natl Cancer Inst Monogr 41

    Google Scholar 

  9. Edsmyr F, Esposti PL, Anderson L (1980) Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate. Scand J Urol Nephrol 55 (Suppl): 135–138

    Google Scholar 

  10. Eisenberger MA, Bezerdjian L, Kalash SA (1987) A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol Clin North Am 14: 695–706

    PubMed  CAS  Google Scholar 

  11. Fossa DS, Miller A (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115: 406–408

    PubMed  CAS  Google Scholar 

  12. Fossa SD, Urnes T, Kaalhus 0 (1987) Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate. Scand J Urol Nephrol 21: 13–16

    CAS  Google Scholar 

  13. Gibbons RP (1987) Prostate cancer chemotherapy. Cancer 60: 586–587

    Article  PubMed  CAS  Google Scholar 

  14. Hall BE, Good JW (1962) Treatment of far advanced cancer with 5 fluorouracil used alone and in combination with irradiation: incidence and duration of remission and survival data in 223 patients. Cancer Chemother Rep 16: 369–386

    PubMed  CAS  Google Scholar 

  15. Hsu DS, Babaian RJ (1983) 5-Fluorouracil, adriamycin, mitomycin-C (FAM) in the treatment of hormonal resistant stage D adenocarcinoma of the prostate (abstract). Proc Am Soc Clin Oncol 133:C 5250

    Google Scholar 

  16. Humphrey EW, Hymes AC, Ausman RK et al (1961) An evaluation of actinomycin-D and mitomycin-C in patients with advanced cancer. Surgery 50: 881–885

    PubMed  CAS  Google Scholar 

  17. Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JC, Minna JD (1980) Effective treatment of hormonally unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. Cancer 45: 1300–1310

    Article  PubMed  CAS  Google Scholar 

  18. Ihde DC, Bunn PA, Cohen MH (1981) Combination chemotherapy as initial treatment for state D 2 prostatic cancer (abstract). Proc Am Assoc Cancer Res 163: 648

    Google Scholar 

  19. Johansson JE, Anderson SOA, Beckman KW, Lingardh G, Zador G (1987) Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 29: 55–59

    Article  PubMed  CAS  Google Scholar 

  20. Jones WG, Fossa SD, Bono AV, Croies JJ, Stoter G, de Pauw M, Sylvester R, members of the EORTC Genito-Urinary Tract Cooperative Group (1986) Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J Urol 4: 182–185

    Google Scholar 

  21. Jonsson G, Hogberg B, Nilsson T (1977) Treatment of advanced prostatic carcinoma with estramustine phosphate ( Estracyt ). Scand J Urol Nephrol 11: 231–238

    Google Scholar 

  22. Kasimis BS, Miller BJ, Kaneshiro CA, Forbes KA, Moran EM, Metter GE (1985) Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin-C (FAM) in the treatment of hormone-resistant metastatic carcinoma of the prostate. A preliminary report of a randomized trial. J Clin Oncol 3: 385–392

    Google Scholar 

  23. Kasimis BS, Moran EM, Miller JB (1983) Treatment of hormone-resistant metastatic cancer of the prostate with 5-FU, doxorubicin and mitomycin-C (FAM): a preliminary report. Cancer Treat Rep 67: 937–939

    PubMed  CAS  Google Scholar 

  24. Kontturi M, Sotarauta M, Tammela T, Lukkarinen O, Romppainen W (1988) Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostate cancer. Eur Urol 15: 43–47

    PubMed  CAS  Google Scholar 

  25. Kuss R, Khoury S, Richard F, Fourcade F, Franz P, Capelle JP (1980) Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52: 29–33

    Article  PubMed  CAS  Google Scholar 

  26. Leistenschneider W, Nagel R (1980) Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry. Eur Urol 6: 111–115

    PubMed  CAS  Google Scholar 

  27. Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon CJ (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat Rep 60: 77–83

    PubMed  CAS  Google Scholar 

  28. Logothetis CJ, Samuels ML, von Eschenbach AC, Trindale A, Ogden S, Grant C, Johnson DE (1983) Doxorubicin, mitomycin-C and 5-fluorouracil ( DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1: 368–378

    Google Scholar 

  29. Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy GP (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide, and adriamycin. J Urol 115: 86–88

    PubMed  CAS  Google Scholar 

  30. Merrin C (1978) Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 119: 522–524

    PubMed  CAS  Google Scholar 

  31. Merrin CE (1979) Treatment of genitourinary tumors with cisdichlorodiammine platinum (II): experience in 250 patients. Cancer Treat Rep 63: 1579–1589

    PubMed  CAS  Google Scholar 

  32. Mittlemen A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J Urol 115: 403–412

    Google Scholar 

  33. Moore GE, Bross IDJ, Ausman R et al (1968) Effects of 5 fluorouracil (NSC-19893) in 389 patients with cancer: Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52: 641–653

    Google Scholar 

  34. Moore MR, Troner MB, DeSimone P, Birch R, Irwin L (1986) Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a southeastern Cancer Study Group Trial. Cancer Treat Rep 70: 451–542

    Google Scholar 

  35. Murphy GP, Natarajan N, Pontes JE, Schmitz RC, Smart CR, Schmidt JP, Mettlin C (1982) The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127: 928–934

    PubMed  CAS  Google Scholar 

  36. Muss HB, Howard V, Richards F et al (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer. Cancer 47: 1949–1953

    Article  PubMed  CAS  Google Scholar 

  37. Nilsson T (1980) Estracyt-clinical experiences. Scand J Urol Nephrol 55 (Suppl): 135–138

    CAS  Google Scholar 

  38. Nissen NI, Pajak TF, Leone LA et al (1980) Clinical trial of neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer 45: 232–235

    Article  PubMed  CAS  Google Scholar 

  39. O’Bryan RM, Luce JK, Talley RW et al (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1–8

    Article  PubMed  Google Scholar 

  40. Paulson DF, Berry WR, Cox EB, Walker A, Laszlo J (1979) Treatment of metastatic endocrine unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response of therapy. J Natl Cancer Inst 63: 615–622

    PubMed  CAS  Google Scholar 

  41. Qazi R, Khandekar J (1983) Phase II study of cisplatin for metastatic prostatic carcinoma: an Eastern Cooperative Oncology Group study. Am J Clin Oncol (CCT) 6: 203–205

    Article  CAS  Google Scholar 

  42. Reiner WG, Scott WW, Eggleston JC, Walsh PC (1979) Long-term survival after hormonal therapy for stage D prostate cancer. J Urol 122: 183–184

    PubMed  CAS  Google Scholar 

  43. Ross RK, Paganini-Hill A, Henderson B (1983) The etiology of prostate cancer: what does epidemiology suggest? Prostate 4: 333–344

    Article  PubMed  CAS  Google Scholar 

  44. Rossof AH, Talley RW, Stephens R et al (1979) Phase II evaluation of cis-dichlorodiammine platinum ( II) in advanced malignancies of the genitourinary and gynecological organs; a Southwest Oncology Group study. Cancer Treatment Rep 63: 1557–1565

    Google Scholar 

  45. Rübben H, Altwein JE (1987) Das fortgeschrittene Prostatakarzinom-Ein therapeutisches Dilemma? Urologe [A] 26: 7–14

    Google Scholar 

  46. Scher H, Yagoda A, Watson R, Serber M, Whitmore W (1984) Phase II trial of adriamycin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131: 1099–1102

    PubMed  CAS  Google Scholar 

  47. Schmidt JD (1983) Combination of chemotherapy and hormones in prostatic cancer. In: Pavone Macaluso M, Smith PH (eds) Cancer of the prostate and kidney. Plenum, New York, p 397

    Google Scholar 

  48. Servadio C, Mukamel E, Kahan E (1984) Carcinoma of the prostate in Israel: some epidemiological and therapeutic considerations. Prostate 5: 375

    Article  PubMed  CAS  Google Scholar 

  49. Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125: 191–195

    PubMed  CAS  Google Scholar 

  50. Soloway MS, Shippel RM, Ikard M (1979) Cyclophosphamide, doxorubicin-hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 122: 637–639

    PubMed  CAS  Google Scholar 

  51. Soloway MS, DeKernion JB, Gibbons RP et al (1981) Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125: 664–667

    PubMed  CAS  Google Scholar 

  52. Soloway MS, Beckley S, Brady MF et al (1983) A comparison of estramustine phosphate versus cisplatin alone versus estramustine-phosphate plus cisplatin in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J Urol 129: 56–61

    PubMed  CAS  Google Scholar 

  53. Stephens RL, Vaughn C, Lane M et al (1984) Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. Cancer 53: 406–410

    Article  PubMed  CAS  Google Scholar 

  54. Torti FM, Aston D, Lum BL et al (1983) Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1: 477–482

    PubMed  CAS  Google Scholar 

  55. Torti FM, Shortliffe LD, Carter SK et al (1985) A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 56: 2580–2586

    Article  PubMed  CAS  Google Scholar 

  56. Uzbicki RM, Amer RH, Al-Sarraf M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma. Cancer Treat Rep 63: 999–1001

    Google Scholar 

  57. Veronesi A, Zattoni F, Frustacci Set al (1982) Estramustine phosphate (Estracyt) treatment of T3–T4 prostatic carcinoma. Prostate 3: 159–164

    Article  PubMed  CAS  Google Scholar 

  58. Walther PJ, Williams StD, Troner M, Greco AF, Birch R, Einhorn LH and the Southeastern Cancer Study Group (1986) Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 70: 771–772

    PubMed  CAS  Google Scholar 

  59. Yagoda A, Watson RC, Natale RB, Bartell W, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cisdiammine-dichloride platinum II. Cancer 44: 1553–1562

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. P. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Universität Würzburg, Luitpoldkrankenhaus, Josef-Schneider-Straße 2, D-8700, Würzburg, Deutschland

    H. G. W. Frohmüller  & M. P. Wirth  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wirth, M.P. (1990). Wertigkeit der Chemotherapie in der Behandlung des fortgeschrittenen Prostatakarzinoms. In: Frohmüller, H.G.W., Wirth, M.P. (eds) Behandlung des fortgeschrittenen Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84064-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84064-7_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52076-4

  • Online ISBN: 978-3-642-84064-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation